南京柯菲平盛辉制药

Nanjing Kefei Ping Shenghui Pharmaceutical is a specialized pharmaceutical manufacturing and development subsidiary of the Nanjing Kefei Ping Pharmaceutical Group. The company is primarily focused on the production and commercialization of innovative small molecule therapies, most notably Bivoprazan (Keverprazan), a potassium-competitive acid blocker (P-CAB) approved in China for gastrointestinal disorders. Located in the Nanjing Jiangbei New Area, the company operates high-standard GMP manufacturing facilities to support its parent group's transition into an innovation-led biopharmaceutical entity. Its portfolio emphasizes treatments for digestive system diseases and cardiovascular health, leveraging advanced chemical synthesis and formulation capabilities.